A 3-day Course for CFS/ME

Summary

Chronic fatigue syndrome/Myalgic encephalomyelitis (CFS/ME) can be a serious and disabling condition with a heavy symptom burden and low function. Work disability is common, and social life dramatically affected. CFS/ME is a challenging health problem as well as a societal problem.

In recent years, a doubling of the number of patients with a CFS/ME diagnoses has been reported in Norway. The patient group represents a challenge for the health care system, the municipality, and the Norwegian Labour and Welfare Organization (NAV). According to new figures, the NAV pays 100 million Norwegian Kroner (NOK) each month in permanently incapacitated expenses for people with CFS/ME. Municipalities have expenses in form of care, rehabilitation and other measures.

There is a lack of effective treatment for CFS/ME. Evidence-based knowledge is highly needed.

If the 3-day course shows promising effects, this could have positive consequences for patients, relatives and health personnel, but also financially for the society and the municipality.

Conditions

• Chronic Fatigue Syndrome
• Myalgic Encephalomyelitis

Interventions

BEHAVIORAL

A 3-day course

The course is built on the LP manual (Parker, 2013) and includes stress theory, Positive Psychology and knowledge about regulating thoughts, feelings and behavior, and through that positively influencing physiology.

BEHAVIORAL

Waiting list

Treatment as usual (TAU) in the first 10 weeks. After 10 weeks: Behavioural: A 3-day course. The course is built on the LP manual (Parker, 2013) and includes stress theory, Positive Psychology and knowledge about regulating thoughts, feelings and behavior, and through that positively influencing physiology.

Sponsors & Collaborators

• University of Oslo

  collaborator OTHER

• Haukeland University Hospital

  collaborator OTHER

• Lørenskog municipality

  collaborator UNKNOWN

• The Research Council of Norway

  collaborator OTHER

• Norwegian University of Science and Technology

  lead OTHER

Principal Investigators

• Leif Edward Ottesen Kennair, PhD prof · NTNU, Department of Psychology

Study Design

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Model

PARALLEL

Eligibility

Min Age

18 Years

Max Age

65 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2022-03-21

Primary Completion

2027-01-01

Completion

2028-12-01

Countries

• Norway

Study Locations